Key Takeaways
- Converge Bio has received a $2.5 million, 37-month grant from the Gates Foundation to extend its generative AI drug modeling platform into crop genomics.
- The grant supports development of a multimodal, long-context foundation model capable of identifying causal genetic variants linked to agricultural traits such as yield and climate resilience.
- Converge Bio's AI treats the crop genome as an interconnected system, analyzing millions of base pairs simultaneously to rank genetic variants most likely driving specific outcomes.
- Traditional crop breeding takes 12 to 15 years to produce a new variety; Converge Bio's platform aims to shorten this timeline by prioritizing the most promising genetic targets earlier in the development cycle.
- The initiative marks Converge Bio's first major expansion from human health into crop science, with a stated goal of supporting long-term global food security.
Converge Bio Receives $2.5 Million Gates Foundation Grant to Extend AI Platform to Crop Genomics
Converge Bio, a generative AI company focused on life sciences, has been awarded a $2.5 million grant from the Gates Foundation to adapt its AI-powered drug modeling platform for crop genomics. The 37-month grant will fund development of a multimodal, long-context foundation model designed to identify causal genetic variants associated with key agricultural traits including yield and climate resilience, extending the company's platform from human health into crop science for the first time.
Traditional crop breeding takes 12 to 15 years to produce a new variety — a timeline that increasingly lags behind the pace of climate change. Converge Bio's approach treats the crop genome as an interconnected system rather than a collection of isolated parts, analyzing millions of base pairs simultaneously to surface the genetic variants most likely driving specific outcomes.
“This collaboration reflects a shared belief that solving the challenges of global food security requires a fundamentally new approach to biology,” said Dov Gertz, CEO and co-founder of Converge Bio. “For us, this is a unique opportunity to bring our core technology into the agricultural space and accelerate the development of crops that are better equipped to withstand environmental stress.”
How Converge Bio's AI Virtual Cell Works in Crop Science
The system functions similarly to a large language model processing a full document: researchers input a DNA sequence and related gene activity data, and the model ranks the genes or mutations most likely driving a target outcome while surfacing which parts of the genome led to those predictions. This interpretability layer is designed to help scientists prioritize candidates for real-world experimental validation, reducing the number of crop breeding cycles needed to develop climate-resilient varieties.
Expanding from Human Health to Global Food Security
The grant marks a significant platform extension for Converge Bio, moving from pharmaceutical applications to crop science at a moment when global food systems face compounding pressure from climate volatility. The initiative aims to help researchers and growers identify high-resilience genetic patterns earlier in the breeding process, minimizing vulnerability to environmental shocks and supporting long-term food supply stability.
